(Alliance News) - Diaceutics PLC said on Tuesday it swung to a pretax profit in 2021 and posted an increase in annual revenue.
The diagnostic commercialisation company for precision testing posted a pretax profit of GBP462,000 in 2021, compared to a loss of GBP682,000 million in 2020.
Diaceutics also increased its revenue by 10% to GBP13.9 million from GBP12.7 million.
It explained that 60% of its revenue came from the DXRX platform, far above the 20% target set by the company. The DXRX platform integrates diagnostic testing data from a global network for laboratories.
"We are confident that Diaceutics is positioned to maximise the advantage it has as the market-first digital diagnostics commercialisation platform," the Belfast-based company said.
Diaceutics shares were 0.5% higher at 103.48 pence each in London on Tuesday afternoon.
By Tom Budszus; tombudszus@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Diaceutics (DXRX)